Urolithin A: Mitochondrial Health, Brain Blood Flow, and What Human Trials Actually Show

Why This New Urolithin A Study Deserves Attention

Urolithin A has attracted considerable interest in longevity medicine because of its relationship with mitochondrial quality control. Much of the discussion has centered on whether promoting the removal of damaged mitochondria might improve muscle function, energy metabolism, or resilience during aging.

Those questions are important, but mitochondria are not confined to skeletal muscle. They are essential to the function of vascular endothelial cells, neurons, immune cells, and other metabolically active tissues. Changes in mitochondrial maintenance could therefore have implications extending across several organ systems.

A randomized clinical trial published October 9, 2026, in JAMA Network Open investigated whether supplementation with urolithin A could improve vascular function in middle-aged adults with obesity. The investigators examined both peripheral endothelial responses and changes in brain hemodynamics during cognitive activity.

The results were mixed, with no significant improvement in the primary vascular outcome but an interesting response in the cerebral measurements. The study provides another opportunity to distinguish evidence of biological activity from demonstrated clinical benefit.

HormoneSynergy® previously examined the foundational human research, including mitophagy, muscle strength, endurance, immune aging, supplementation doses, and the limitations of commercial longevity claims. That broader review remains available in Urolithin A Benefits and Mitophagy: What Human Trials Actually Show. The present article focuses on the newly published vascular findings and how they fit into the existing clinical evidence.

What Is Urolithin A?

Urolithin A is a postbiotic metabolite that certain intestinal bacteria produce when they process ellagitannins and ellagic acid. These plant compounds occur in foods such as pomegranates, walnuts, raspberries, strawberries, and several other fruits and nuts.

The ability to produce urolithin A varies among individuals because it depends partly on the composition and metabolic capabilities of the intestinal microbiome. Two people consuming similar amounts of the same foods may therefore generate substantially different concentrations of the compound.

Direct supplementation bypasses this microbial conversion step, providing a defined dose that can be studied more consistently. This does not mean that supplementation reproduces every biological effect associated with consuming ellagitannin-rich foods, which also provide fiber, micronutrients, and other plant compounds.

The principal scientific interest in urolithin A concerns mitophagy, one component of the cellular maintenance system responsible for recognizing and removing damaged mitochondria.

Mitophagy and the Biology of Mitochondrial Aging

Mitochondria are often described as the energy-producing structures within cells because they participate in the production of adenosine triphosphate, or ATP. Their functions are considerably broader, involving cellular signaling, metabolic regulation, oxidative stress responses, and programmed cell death.

With aging, mitochondrial function can become less efficient, while the systems responsible for mitochondrial repair and replacement may also change. These alterations can contribute to declining physical performance and reduced cellular resilience, although their extent varies among tissues and individuals.

Mitophagy allows cells to identify and recycle mitochondria that are damaged or no longer functioning appropriately. This is part of a larger quality-control network that includes mitochondrial biogenesis, fusion and fission, protein maintenance, and adaptations to changing energy demands.

Experimental studies have shown that urolithin A can influence pathways involved in mitophagy. Human studies have also reported changes in proteins, gene expression, metabolites, and other markers associated with mitochondrial biology.

Those findings support the idea that urolithin A is biologically active in humans. Whether the observed molecular changes consistently produce better physical performance, vascular health, cognitive function, or long-term disease outcomes remains an important question.

The October 2026 Randomized Clinical Trial

Researchers at the University of Oklahoma Health Campus conducted a randomized, double-blind, placebo-controlled trial involving 50 adults ages 40 to 64 with obesity. Participants had a body mass index of at least 30, and the average BMI was approximately 38.3. The average age was 50.7 years, and 74% of participants were women.

Twenty-five participants were assigned to receive 1,000 mg of urolithin A daily, while 25 received placebo. The active intervention consisted of two divided daily doses and continued for four weeks. Seven participants did not complete follow-up, producing a 14% dropout rate.

The investigators selected brachial artery flow-mediated dilation as their primary outcome. They also measured other aspects of peripheral vascular function and assessed brain hemodynamic responses during cognitive testing.

This design is relevant because obesity is associated with disturbances in metabolic regulation, endothelial function, and inflammatory signaling. Mitochondrial dysfunction is one proposed contributor to these changes, making urolithin A a plausible experimental intervention.

The trial was primarily a proof-of-concept investigation. Its relatively short duration and modest sample size were better suited to identifying possible physiological signals than establishing whether supplementation can prevent cardiovascular or neurological disease.

Read the October 9, 2026 randomized clinical trial in JAMA Network Open.

Peripheral Endothelial Function: The Primary Outcome Was Not Significant

The endothelium is the thin cellular lining of blood vessels. It participates in regulating vascular tone, blood flow, inflammatory signaling, clotting, and the interaction between circulating blood and the vessel wall.

One commonly used research measurement of endothelial function is flow-mediated dilation, or FMD. During this test, blood flow through an artery is temporarily restricted and then restored. Ultrasound is used to determine how much the artery dilates in response to the resulting increase in blood flow.

Impaired endothelial function is associated with cardiometabolic disease and cardiovascular risk. Improvements in endothelial physiology are therefore of interest, although changes in FMD are not interchangeable with reductions in heart attacks, strokes, or other clinical events.

After four weeks, the average change in flow-mediated dilation was approximately 1.3% in the urolithin A group and 0.3% in the placebo group. Variability was substantial, and the between-group difference was not statistically significant.

Other measurements of peripheral vascular function, including assessments of reactive hyperemia and reperfusion, also failed to demonstrate significant treatment benefits.

These findings do not establish that urolithin A has no vascular activity under any circumstances. Four weeks may be insufficient for some interventions, and responses could differ by age, metabolic health, vascular disease burden, or other individual characteristics. Nevertheless, the trial did not demonstrate the improvement in peripheral endothelial function that investigators had anticipated.

Brain Blood Flow: A More Interesting Signal

The cerebral findings differed from the peripheral vascular results.

During cognitive testing, investigators measured hemodynamic responses associated with neural activity. Participants receiving urolithin A demonstrated significantly greater task-evoked responses than those receiving placebo.

In the reported analysis, the mean hemodynamic response coefficient was approximately 15.53 in the urolithin A group compared with -1.43 in the placebo group. These values represent modeled task-related hemodynamic signals, not percentages of increased cerebral blood flow.

The findings suggest that supplementation may influence how the brain's vascular system responds during cognitive activity. However, the study did not establish a sustained increase in resting cerebral blood flow, nor did it show that the observed response translated into better memory, processing speed, or other cognitive performance outcomes.

Participants did not demonstrate a significant improvement in task performance despite the changes in hemodynamic measurements.

The distinction is clinically important. Brain hemodynamic activity is a physiological measurement that can help researchers investigate cerebral vascular regulation. Greater task-evoked activity does not automatically mean that the brain is functioning better or that an intervention protects against cognitive decline.

Understanding Neurovascular Coupling

The brain consumes substantial amounts of energy despite representing a relatively small proportion of body weight. Its energy demands vary continuously as different neural networks become active.

Neurovascular coupling describes the coordinated relationship between neuronal activity and local vascular responses. When a region of the brain becomes active, signaling among neurons, astrocytes, vascular cells, and surrounding tissues helps regulate the delivery of oxygen and nutrients.

Healthy neurovascular regulation depends on several interacting systems, including endothelial function, nitric oxide signaling, cellular metabolism, and the integrity of the brain's microcirculation.

Changes in neurovascular coupling have been investigated in aging, metabolic disease, hypertension, and cognitive impairment. Because mitochondrial dysfunction can influence cellular energy balance and vascular signaling, interventions targeting mitochondrial biology may also affect aspects of this system.

Urolithin A provides one possible avenue for investigating these connections. The October trial identified a hemodynamic response that merits replication, but it did not demonstrate that supplementation corrected impaired neurovascular coupling or improved clinically meaningful cognitive function.

Does This Mean Urolithin A Improves Cognition?

Not yet. The distinction between cerebral hemodynamic responses and cognitive performance is central to interpreting the study.

A physiological response may indicate that an intervention has influenced a particular biological pathway. Whether that change is beneficial, neutral, or clinically meaningful requires additional evidence.

In this trial, the measurable response during cognitive activity was not accompanied by improved performance on the tasks themselves. The findings therefore do not support presenting urolithin A as a proven memory supplement or cognitive enhancer.

It is possible that changes in vascular responsiveness precede measurable functional improvements, particularly when studying interventions over only a few weeks. That remains a hypothesis rather than an established explanation for these findings.

Longer randomized trials incorporating validated cognitive testing, measures of neurovascular function, and appropriate clinical populations will be needed to determine whether the observed signal has practical significance.

How the New Study Fits With Previous Human Research

Urolithin A has progressed further into human investigation than many supplements promoted for mitochondrial health. Randomized studies have examined muscle performance, mitochondrial biomarkers, immune-cell function, and, now, vascular physiology.

Muscle Strength and Exercise Performance

A randomized trial published in Cell Reports Medicine in 2022 enrolled 88 overweight, untrained middle-aged adults. Participants received placebo, 500 mg of urolithin A, or 1,000 mg daily for four months.

Investigators reported improvements in selected hamstring-strength measurements and changes in biomarkers associated with mitochondrial metabolism and inflammation.

The results were not uniform. The primary exercise-performance endpoint was not significantly improved, and the study did not establish consistent benefits across all muscle groups or an increase in lean body mass.

The findings nevertheless provided evidence that supplementation could influence measurable aspects of muscle physiology in humans, supporting additional investigation in older and metabolically vulnerable populations.

Muscle Endurance in Older Adults

Another randomized trial published in JAMA Network Open enrolled 66 adults ages 65 to 90 who received either 1,000 mg of urolithin A daily or placebo for four months.

Some secondary measures of hand and leg muscle endurance improved among those receiving urolithin A. Investigators also reported changes in plasma biomarkers related to mitochondrial metabolism and inflammation.

The prespecified primary outcomes, involving six-minute walking distance and maximal ATP production in hand muscle, did not show significant between-group improvements.

These results suggest a possible muscle-endurance effect, but they do not establish broad improvement in mobility, physical independence, or skeletal muscle function.

Immune Aging

A randomized study published in Nature Aging in 2025 examined urolithin A supplementation in healthy middle-aged adults. The four-week study identified changes involving immune-cell populations, mitochondrial metabolism, and selected measures of immune-cell function.

These findings expanded interest in urolithin A beyond skeletal muscle and raised questions about how mitochondrial maintenance interacts with immune aging.

As with the newer cerebral findings, changes in cellular measurements do not by themselves demonstrate reduced infections, lower chronic disease risk, or improved long-term health.

The July 2026 Systematic Review

A systematic review published in July 2026 evaluated randomized human trials of urolithin A and muscle-related outcomes. The investigators identified five eligible trials involving 236 participants.

Different participant populations, treatment durations, and outcome measurements limited the ability to combine results. Only the six-minute walk outcome could be pooled, and the estimated improvement was not statistically significant. The certainty of that evidence was rated low.

The review supported continued study while emphasizing that available trials were too small and heterogeneous to establish reliable benefits across strength, endurance, and physical performance outcomes.

The October 2026 vascular trial adds a new research question to this evidence base. It does not resolve the uncertainties identified in the earlier muscle studies.

For a more detailed examination of the earlier clinical trials, study limitations, doses, and supplement quality considerations, see HormoneSynergy's original review: Urolithin A Benefits and Mitophagy: What Human Trials Actually Show.

Why Mitochondrial Health and Vascular Function Are Connected

Vascular endothelial cells depend on mitochondrial signaling even though their energy production differs from that of highly oxidative tissues such as skeletal muscle and cardiac muscle.

Mitochondria help regulate redox balance, calcium signaling, cell survival, inflammatory responses, and communication between metabolic activity and vascular behavior.

Obesity, insulin resistance, elevated blood pressure, and other cardiometabolic disturbances can affect endothelial physiology through several interacting mechanisms. These include oxidative stress, altered nitric oxide availability, chronic inflammatory signaling, and changes in mitochondrial function.

Researchers are interested in whether improving mitochondrial quality control could influence these processes and help maintain vascular resilience.

However, vascular aging is not exclusively a mitochondrial disorder. Arterial stiffness, blood pressure, lipid exposure, glycemic regulation, inflammation, vascular structure, and accumulated atherosclerotic disease all contribute to cardiovascular risk.

The October trial illustrates the complexity of these relationships. A measurable effect involving brain hemodynamics occurred without significant improvement in the primary peripheral endothelial outcome. Different vascular beds may respond differently to interventions, and a short study cannot determine why those differences occurred.

Does the New Trial Support Urolithin A for Cardiovascular Prevention?

The new findings are insufficient to recommend urolithin A as a treatment for endothelial dysfunction or as a strategy proven to prevent cardiovascular disease.

Flow-mediated dilation and other vascular measurements are valuable research tools, but they are not substitutes for trials assessing cardiovascular events or clinically meaningful changes in vascular disease.

No large randomized outcome trial has established that urolithin A supplementation reduces heart attacks, strokes, cardiovascular mortality, or atherosclerotic plaque progression.

The absence of a statistically significant peripheral vascular benefit in the October study also means that this trial cannot be used as positive evidence for cardiovascular protection.

The more interesting question is whether longer studies in appropriately selected populations might identify changes in microvascular regulation, cerebral hemodynamics, or other physiological measures that translate into meaningful outcomes.

Limitations of the October Trial

The study's randomized, placebo-controlled design is an important strength. It also examined multiple vascular measurements rather than relying exclusively on self-reported symptoms or nonspecific descriptions of improved energy.

Several limitations influence how broadly its findings should be interpreted.

Only 50 participants were randomized, seven did not complete follow-up, and treatment lasted four weeks. The participants were predominantly women and had obesity, with a mean BMI above 38. These characteristics limit direct application to lean, physically active older adults or people with different metabolic profiles.

Approximately one in five participants was taking a GLP-1 or GIP-related medication. The researchers examined potential confounding in additional analyses and did not identify a meaningful change in the primary treatment estimate, but the sample was too small to resolve all questions about treatment interactions.

The positive brain hemodynamic finding was a secondary outcome. Although statistically significant, it requires replication with larger samples and appropriate adjustment and interpretation across multiple measures.

Most importantly, the trial did not demonstrate improved cognitive performance, reduced vascular disease, or better long-term health outcomes.

These limitations do not diminish the value of the investigation. They help define the next clinical questions that should be studied.

What About Dosage and Safety?

The October 2026 study used 1,000 mg of urolithin A daily for four weeks, administered in two divided doses. Previous randomized trials have commonly investigated 500 mg or 1,000 mg daily over periods ranging from several weeks to four months.

These are research doses, not an established prescription for mitochondrial health, cognition, cardiovascular protection, or longevity.

Short-term studies have generally found urolithin A to be well tolerated, including the new vascular trial. However, the available trials are relatively small and of limited duration.

Long-term safety, uncommon adverse effects, medication interactions, and outcomes in people with significant cardiovascular, neurological, or other chronic medical conditions remain less well characterized.

Supplement quality also deserves attention. A product should clearly disclose the amount of urolithin A, provide evidence of identity and purity testing, and avoid relying on proprietary blends or claims that have not been evaluated in clinical trials.

Additional ingredients should not be assumed to improve efficacy simply because they also appear in discussions of mitochondrial biology or healthy aging.

Clinical Implications for Preventive Longevity Medicine

The new research is relevant to an increasingly integrated understanding of metabolic, vascular, muscular, and cognitive aging.

Endothelial health and cerebral circulation are influenced by many of the same factors that affect long-term cardiovascular risk. Insulin resistance, hypertension, impaired lipid metabolism, excess visceral adiposity, physical inactivity, and vascular disease can influence both systemic and cerebral physiology.

Mitochondrial biology is part of that interconnected picture. A compound capable of altering mitochondrial quality-control pathways may eventually provide additional therapeutic opportunities, but its role must be demonstrated through reproducible clinical outcomes.

For patients with declining exercise tolerance, muscle weakness, fatigue, or concerns about cognitive health, the initial priority remains identifying potentially treatable causes. These may involve inadequate nutrition, sleep disorders, metabolic dysfunction, medications, hormone abnormalities, cardiovascular disease, or neurological conditions.

Preserving muscular strength, maintaining aerobic fitness, managing cardiometabolic risk, and addressing established vascular disease have a substantially stronger evidence base than urolithin A supplementation alone.

Objective measurements can help place emerging interventions in an appropriate context. Body composition assessment, strength and functional testing, metabolic laboratory evaluation, vascular assessment, and cognitive testing may be useful when clinically indicated.

The HormoneSynergy® Approach

HormoneSynergy® approaches mitochondrial health as one component of comprehensive preventive longevity medicine rather than an isolated target for supplementation.

Under the clinical leadership of Dr. Kathryn Retzler, the practice emphasizes identifying metabolic, cardiovascular, cognitive, hormonal, and functional changes that may influence healthspan. Treatment decisions are guided by individual clinical findings, established evidence, and longitudinal assessment.

The urolithin A research is encouraging because investigators are moving beyond laboratory demonstrations of mitophagy into controlled human studies examining physical and physiological outcomes. The October vascular trial adds an especially interesting question concerning the relationship between mitochondrial biology and cerebral hemodynamic regulation.

At the same time, the current research does not support presenting urolithin A as an established therapy for improving cognition, preventing vascular disease, or reversing aging. The available trials have identified biological activity and selected functional signals, but many clinically important outcomes remain uncertain.

HormoneSynergy® considers supplementation within the larger context of nutrition, resistance training, cardiovascular fitness, sleep, metabolic health, and appropriate medical care. For patients interested in emerging mitochondrial interventions, attention to measurable outcomes and supplement quality is more useful than relying on generalized claims of cellular rejuvenation.

The clinical interest in urolithin A remains constructive. Its mechanisms deserve further study, particularly if future investigations establish that changes in mitochondrial maintenance lead to meaningful improvements in vascular or neurological function.

What Future Research Needs to Establish

The next generation of studies should determine whether the cerebral hemodynamic response observed after four weeks can be reproduced in larger and more diverse populations.

Longer intervention periods may help clarify whether effects on neurovascular regulation persist and whether they are accompanied by improvements in objective cognitive measures.

Studies should also investigate whether responses vary according to obesity, insulin resistance, blood pressure, age, sex, vascular disease burden, or baseline mitochondrial function.

Comparisons with exercise and established cardiometabolic interventions may help determine whether supplementation provides additional benefit rather than merely producing changes in overlapping biological pathways.

The most compelling future evidence would connect reproducible physiological changes to better physical function, cognition, vascular outcomes, or other meaningful measures of healthspan.

Until those data are available, urolithin A remains an interesting emerging intervention with demonstrated biological activity, promising areas for investigation, and a clinical evidence base that is still developing.

Related HormoneSynergy® Resources

• Urolithin A Benefits and Mitophagy: What Human Trials Actually Show — Foundational research review, dosage, muscle function, immune aging, supplement quality, and clinical limitations
• The HormoneSynergy® Longevity Medicine Model
• Optimal Aging Assessment
• Body Composition and Longevity Medicine
• DEXA Body Composition and Bone Density
• Preventive Cardiology and Longevity Medicine
• Medicine, Not Marketing
• HormoneSynergy® Longevity Medicine Resource Library

Selected Research and References

1. da Costa Pinaffi-Langley AC, Gulej R, Kaposzta Z, et al. Urolithin A and endothelial and cerebrovascular function in middle-aged adults with obesity: A randomized clinical trial. JAMA Network Open. 2026;9(10):e2638047. https://doi.org/10.1001/jamanetworkopen.2026.38047
2. Singh A, et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Reports Medicine. 2022. Read the study.
3. Liu S, D'Amico D, Shankland E, et al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: A randomized clinical trial. JAMA Network Open. 2022. Read the study.
4. Denk D, et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: A randomized, placebo-controlled trial. Nature Aging. 2025.
5. Dao T, et al. Effects of urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. Frontiers in Nutrition. 2026.
6. Andreux PA, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019.

Frequently Asked Questions

Does urolithin A improve blood flow to the brain?

A randomized trial published in October 2026 found that participants receiving urolithin A demonstrated greater brain hemodynamic responses during cognitive testing. The study did not establish improved resting cerebral blood flow or better cognitive performance. Larger trials are needed to determine the clinical significance of these findings.

Does urolithin A improve endothelial function?

In the October 2026 randomized trial, four weeks of urolithin A supplementation did not significantly improve brachial artery flow-mediated dilation or other peripheral endothelial function measurements in middle-aged adults with obesity.

Can urolithin A prevent dementia or Alzheimer's disease?

There is currently insufficient clinical evidence to conclude that urolithin A prevents dementia, Alzheimer's disease, or age-related cognitive decline. The recent cerebral hemodynamic findings are preliminary and were not accompanied by improved cognitive task performance.

Does urolithin A improve mitochondrial health?

Human trials have reported changes in biomarkers associated with mitochondrial metabolism and quality control. Some studies have also identified improvements in selected muscle endurance or strength measurements. These findings do not establish that supplementation reverses mitochondrial aging or consistently improves physical function.

What dose of urolithin A has been studied?

Randomized human trials have commonly studied 500 mg or 1,000 mg daily. The October 2026 vascular trial used 1,000 mg daily for four weeks. These are research doses, and no dose has been established for preventing cognitive decline, cardiovascular disease, or biological aging.

Can urolithin A replace exercise?

No. Urolithin A has not been shown to reproduce the broad muscular, metabolic, cardiovascular, and neurological adaptations associated with regular physical activity. Resistance training and aerobic exercise remain foundational interventions for healthy aging.

Editorial Transparency: This article evaluates peer-reviewed human research and distinguishes changes in molecular and physiological measurements from demonstrated clinical outcomes. No product endorsement is implied by discussion of a studied ingredient. Research findings should be interpreted in the context of study design, sample size, funding, and independent replication.

About HormoneSynergy®: HormoneSynergy® provides evidence-based preventive longevity medicine in Portland and Lake Oswego, Oregon, under the clinical leadership of Dr. Kathryn Retzler. The clinic integrates advanced assessment, individualized treatment, and long-term monitoring with an emphasis on cardiovascular, metabolic, hormonal, cognitive, and physical health.

Medical Disclaimer: This article is educational and does not constitute individualized medical advice. Dietary supplements can vary in composition and quality, and their use should be discussed with an appropriate healthcare professional, particularly when managing chronic medical conditions or taking prescription medications.